The association between pan-immune-inflammation value and survival in head and neck squamous cell carcinoma.

Autor: Guven, Deniz Can, Erul, Enes, Yilmaz, Feride, Yasar, Serkan, Yildirim, Hasan Cagri, Ercan, Fatih, Kaygusuz, Yunus, Cayiroz, Kerim, Ucdal, Mete Tugcan, Yesil, Furkan, Yazici, Gozde, Cengiz, Mustafa, Gullu, Ibrahim, Aksoy, Sercan
Předmět:
Zdroj: European Archives of Oto-Rhino-Laryngology; May2023, Vol. 280 Issue 5, p2471-2478, 8p
Abstrakt: Purpose: A significant portion of patients with locally advanced head and neck squamous cell carcinoma (HNSCC) relapse despite multimodality treatment denoting the need for biomarkers. The pan-immune-inflammation value (PIV) is a recently developed blood count-based prognostic biomarker. We evaluated the relationship between PIV and survival in locally advanced HNSCC patients treated with chemoradiotherapy (CRT). Methods: A total of 199 patients who underwent CRT at Hacettepe University Oncology Hospital were included. The relationship between clinical and laboratory parameters with overall survival (OS) and disease-free survival (DFS) was analyzed by multivariate analyses. Results: The median age was 59 years and 90.5% of the patients were male. 66.8% of the patients had laryngeal primaries, and 78.9% had T3–T4 disease. 84.9% of the patients received CRT with cisplatin. The optimal PIV threshold value was calculated as 404 in ROC analyses. This PIV value had 75.8% sensitivity and 70.4% specificity for OS prediction (AUC 0.781; 95% CI 0.715–0.846; p < 0.001). In multivariate analyses, high PIV levels (≤ 404 vs. > 404, HR 2.862; 95% CI 1.553–5.276; p = 0.001), higher NLR (≤ 2.5 vs. > 2.5, HR 1.827; 95% CI 1.017–3.281; p = 0.044) levels and ECOG performance score of 2 (HR 2.267; 95% CI 1.385–3.711; p = 0.001) were associated with shorter OS. These factors were associated with shorter DFS also (HR for PIV 2.485, 95% CI 1.383–4.467, p = 0.002). Conclusions: We observed shorter OS and DFS in locally advanced HNSCC patients with high PIV levels. If prospective studies support our findings, the PIV score could be a prognostic biomarker in HNSCC. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: